Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jan;41(1):175–179. doi: 10.1128/aac.41.1.175

Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV.

D M Breines 1, S Ouabdesselam 1, E Y Ng 1, J Tankovic 1, S Shah 1, C J Soussy 1, D C Hooper 1
PMCID: PMC163680  PMID: 8980775

Abstract

The locus nfxD, which contributes to high-level quinolone resistance in Escherichia coli KF111b (gyrAr nfxB nfxD), is only expressed in the presence of a gyrA mutation, and maps to the region of the parC and parE genes, was outcrossed into strain KF130, creating strain DH161 (gyrAr nfxD). DNA sequence analysis of DH161 revealed no changes in the topoisomerase IV parC quinolone resistance-determining region but did identify a single T-to-A mutation in parE at codon 445, leading to a change from Leu to His. Full-length cloned parE+ partially complemented the resistance phenotype in KF111b and DH161, but did not complement the resistance phenotype in strain KF130 (gyrAr). No complementation was seen with cloned, truncated parE+. To confirm these findings, gyrAr was first outcrossed from KF130 into E. coli W3110parE10 [parE temperature sensitive(Ts)] and KL16. The transduced strains KL16 and W3110parE10 were subsequently transformed with plasmids containing cloned parE from DH161 or KL16. Cloned parE from DH161 increased norfloxacin resistance in the parE(Ts) background twofold at 30 degrees C and fourfold at 42 degrees C compared to those for cloned parE from KL16. The same experiment with a non-Ts background revealed a twofold increase in the norfloxacin MIC at both 30 and 42 degrees C. These data identify the nfxD conditional resistance locus as a mutant allele of parE. This report is the first of a quinolone-resistant parE mutant and confirms the role of topoisomerase IV as a secondary target of norfloxacin in E. coli.

Full Text

The Full Text of this article is available as a PDF (191.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger J. M., Gamblin S. J., Harrison S. C., Wang J. C. Structure and mechanism of DNA topoisomerase II. Nature. 1996 Jan 18;379(6562):225–232. doi: 10.1038/379225a0. [DOI] [PubMed] [Google Scholar]
  2. Chung C. T., Niemela S. L., Miller R. H. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2172–2175. doi: 10.1073/pnas.86.7.2172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Crumplin G. C., Kenwright M., Hirst T. Investigations into the mechanism of action of the antibacterial agent norfloxacin. J Antimicrob Chemother. 1984 May;13 (Suppl B):9–23. doi: 10.1093/jac/13.suppl_b.9. [DOI] [PubMed] [Google Scholar]
  4. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol. 1994 Aug;13(4):641–653. doi: 10.1111/j.1365-2958.1994.tb00458.x. [DOI] [PubMed] [Google Scholar]
  5. Gensberg K., Jin Y. F., Piddock L. J. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium. FEMS Microbiol Lett. 1995 Oct 1;132(1-2):57–60. doi: 10.1111/j.1574-6968.1995.tb07810.x. [DOI] [PubMed] [Google Scholar]
  6. Hane M. W., Wood T. H. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J Bacteriol. 1969 Jul;99(1):238–241. doi: 10.1128/jb.99.1.238-241.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother. 1996 Apr;40(4):879–885. doi: 10.1128/aac.40.4.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hooper D. C., Wolfson J. S., Bozza M. A., Ng E. Y. Genetics and regulation of outer membrane protein expression by quinolone resistance loci nfxB, nfxC, and cfxB. Antimicrob Agents Chemother. 1992 May;36(5):1151–1154. doi: 10.1128/aac.36.5.1151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hooper D. C., Wolfson J. S., Souza K. S., Tung C., McHugh G. L., Swartz M. N. Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli. Antimicrob Agents Chemother. 1986 Apr;29(4):639–644. doi: 10.1128/aac.29.4.639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Ito H., Yoshida H., Bogaki-Shonai M., Niga T., Hattori H., Nakamura S. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob Agents Chemother. 1994 Sep;38(9):2014–2023. doi: 10.1128/aac.38.9.2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kato J., Nishimura Y., Imamura R., Niki H., Hiraga S., Suzuki H. New topoisomerase essential for chromosome segregation in E. coli. Cell. 1990 Oct 19;63(2):393–404. doi: 10.1016/0092-8674(90)90172-b. [DOI] [PubMed] [Google Scholar]
  12. Kato J., Suzuki H., Ikeda H. Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem. 1992 Dec 25;267(36):25676–25684. [PubMed] [Google Scholar]
  13. Khodursky A. B., Zechiedrich E. L., Cozzarelli N. R. Topoisomerase IV is a target of quinolones in Escherichia coli. Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11801–11805. doi: 10.1073/pnas.92.25.11801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kirchhausen T., Wang J. C., Harrison S. C. DNA gyrase and its complexes with DNA: direct observation by electron microscopy. Cell. 1985 Jul;41(3):933–943. doi: 10.1016/s0092-8674(85)80074-x. [DOI] [PubMed] [Google Scholar]
  15. Kumagai Y., Kato J. I., Hoshino K., Akasaka T., Sato K., Ikeda H. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother. 1996 Mar;40(3):710–714. doi: 10.1128/aac.40.3.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nakamura S., Nakamura M., Kojima T., Yoshida H. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob Agents Chemother. 1989 Feb;33(2):254–255. doi: 10.1128/aac.33.2.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ng E. Y., Trucksis M., Hooper D. C. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug;40(8):1881–1888. doi: 10.1128/aac.40.8.1881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pan X. S., Fisher L. M. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J Bacteriol. 1996 Jul;178(14):4060–4069. doi: 10.1128/jb.178.14.4060-4069.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Peng H., Marians K. J. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem. 1993 Nov 15;268(32):24481–24490. [PubMed] [Google Scholar]
  20. Rau D. C., Gellert M., Thoma F., Maxwell A. Structure of the DNA gyrase-DNA complex as revealed by transient electric dichroism. J Mol Biol. 1987 Feb 5;193(3):555–569. doi: 10.1016/0022-2836(87)90266-x. [DOI] [PubMed] [Google Scholar]
  21. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shen L. L., Baranowski J., Pernet A. G. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA. Biochemistry. 1989 May 2;28(9):3879–3885. doi: 10.1021/bi00435a038. [DOI] [PubMed] [Google Scholar]
  23. Soussy C. J., Wolfson J. S., Ng E. Y., Hooper D. C. Limitations of plasmid complementation test for determination of quinolone resistance due to changes in the gyrase A protein and identification of conditional quinolone resistance locus. Antimicrob Agents Chemother. 1993 Dec;37(12):2588–2592. doi: 10.1128/aac.37.12.2588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Vila J., Ruiz J., Goñi P., De Anta M. T. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1996 Feb;40(2):491–493. doi: 10.1128/aac.40.2.491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yamagishi J., Kojima T., Oyamada Y., Fujimoto K., Hattori H., Nakamura S., Inoue M. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1996 May;40(5):1157–1163. doi: 10.1128/aac.40.5.1157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yoshida H., Bogaki M., Nakamura M., Yamanaka L. M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647–1650. doi: 10.1128/aac.35.8.1647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Yoshida H., Kojima T., Yamagishi J., Nakamura S. Quinolone-resistant mutations of the gyrA gene of Escherichia coli. Mol Gen Genet. 1988 Jan;211(1):1–7. doi: 10.1007/BF00338386. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES